A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Mitomycin (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OLYMPUS
- Sponsors UroGen Pharma
- 03 Apr 2018 According to an UroGen Pharma media release, interim analysis for this study will be presented, in an oral presentation, at the 113th American Urological Association's (AUA) Annual Meeting 2018.
- 15 Mar 2018 According to an UroGen Pharma media release, the top-line data from this study are expected in Q3 2018 and assuming positive results the company have planned submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in Q1 2019.
- 15 Mar 2018 According to an UroGen Pharma media release, the company will present an interim analysis from this pivotal trial at an upcoming medical meeting.